In the article on the Multiparameter Analysis of Irofulven Visual Toxicity in the November 15, 2004 issue of Clinical Cancer Research, there was an error in Figure 3. The correct figure appears below.

Fig. 3
Fig. 3. Rates of visual events according to dose administered in first infusion in mg/kg (A) and mg/m2 (B) in phase I-II single agent irofulven clinical trials.
View largeDownload slide

Rates of visual events according to dose administered in first infusion in mg/kg (A) and mg/m2 (B) in phase I-II single agent irofulven clinical trials.

Fig. 3
Fig. 3. Rates of visual events according to dose administered in first infusion in mg/kg (A) and mg/m2 (B) in phase I-II single agent irofulven clinical trials.
View largeDownload slide

Rates of visual events according to dose administered in first infusion in mg/kg (A) and mg/m2 (B) in phase I-II single agent irofulven clinical trials.

Close modal

Raymond E, Kahatt C, Rigolet MH, et al. Characterization and multiparameter analysis of visual adverse agents in irofulven single-agent phase I and II trials. Clin Cancer Res 2004:10:7566–74.

View Original Article
American Association for Cancer Research
2005